Changeflow GovPing Pharma & Drug Safety Metagenomi RuvC domain enzymes, gene editing pa...
Routine Rule Added Final

Metagenomi RuvC domain enzymes, gene editing patent

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3924482A1 for Metagenomi Therapeutics, Inc., covering enzymes with RuvC domains used in gene editing applications. The patent designates all EU member states and several other European countries. Inventors include Brian Thomas, Christopher Brown, Rose Kantor, and others.

What changed

The EPO published a patent application for RuvC domain enzymes filed by Metagenomi Therapeutics, Inc. The patent covers gene editing technology including applications in C12N 9/22 (nucleic acid enzymes), C12N 15/113 (nucleic acid sequences), and C12N 15/90 (stable integration of nucleic acids). The patent designates all EU member states and other European countries.

Gene editing companies, biotech firms, and pharmaceutical developers should review the patent claims to assess potential licensing needs or freedom-to-operate considerations in the EU market.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ENZYMES WITH RUVC DOMAINS

Publication EP3924482A1 Kind: A1 Apr 01, 2026

Applicants

Metagenomi Therapeutics, Inc.

Inventors

THOMAS, Brian, BROWN, Christopher, KANTOR, Rose, DEVOTO, Audra, BUTTERFIELD, Cristina, ALEXANDER, Lisa, GOLTSMAN, Daniela S. A., LIU, Jason

IPC Classifications

C12N 9/22 20060101AFI20230224BHEP C12N 15/113 20100101ALI20230224BHEP C12N 15/10 20060101ALI20230224BHEP C12N 15/90 20060101ALI20230224BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3924482A1

Who this affects

Applies to
Biotechnology companies Pharmaceutical companies Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent examination IP licensing Gene therapy development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.